Bortezomib Completed Phase 3 Trials for Multiple Myeloma (MM) / Effects of Chemotherapy Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03402295Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
NCT02811978Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
NCT01109004Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
NCT01818752Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
NCT01146834Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
NCT01568866Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
NCT01539083Velcade (Bortezomib) Consolidation After Transplant
NCT01916252Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
NCT01063179Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
NCT01910987Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib
NCT00048230PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT00063726A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
NCT00103506Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
NCT00111748UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
NCT00111319VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
NCT00416208Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
NCT00416273A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
NCT00417911Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients
NCT00443235GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
NCT00461747GEM05 for Patients With Multiple Myeloma Under 65 Years
NCT00507416Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
NCT00546780A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
NCT00602511Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
NCT00722566A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma
NCT00773747Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)
NCT00813150Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
NCT01023308Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
NCT01530594Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma
NCT01801436A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
NCT01971658Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)